Enhancing the potential benefits of HIV post-exposure prophylaxis

AIDS

Volumn 20, Issue 14, 2006, Pages 1889-1890

  Roland, Michelle E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COUNSELING; DISEASE TRANSMISSION; FRANCE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; NOTE; PRIORITY JOURNAL; SEXUAL BEHAVIOR;

COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; RISK-TAKING; SEXUAL BEHAVIOR;

EID: 33748480646     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000244209.26253.8b     Document Type: Note

References (14)

1. Herida MLC, Lot F, Laporte A, Desenclos J, Hamers F. Cost-effectiveness of HIV post-exposure prohylaxis in France, 1999-2003. AIDS 2006; 20:1753-1761.
2. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS 2002; 16:397-405.
3. Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JSG, O'Shaughnessy MV, Hogg RS. Prescribing practices in a population-based HIV postexposure prophylaxis program. AIDS 2002; 16:1067-1070.
4. Merchant RC, Keshavarz R. Emergency prophylaxis following needle-stick injuries and sexual exposures: results from a survey comparing New York Emergency Department practitioners with their national colleagues. Mt Sinai J Med 2003; 70:338-343.
5. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164:46-54.
6. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18:2065-2073.
7. Low-Beer S, Weber AE, Bartholomew K, Landolt M, Oram D, Montaner JSG, et al. A reality check: the cost of making postexposure prophylaxis available to gay and bisexual men at high sexual risk [Letter]. AIDS 2000; 14:325-326.
8. Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after nonoccupational HIV exposure: clinical, ethical, and policy considerations [see Comments]. JAMA 1998; 280:1769-1773.
9. Pinkerton SD, Holtgrave DR. Prophylaxis after sexual exposure to HIV [Letter; Comment]. Ann Intern Med 1998; 129:671; discussion 672.
10. Pinkerton SD, Holtgrave DR, Kahn JG. Is post-exposure prophylaxis affordable? [Letter; Comment]. AIDS 2000; 14:325.
11. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recommendations and Reports 2005; 54:RR-2.
12. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-1513.
13. Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787-792.
14. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004; 39:395-401.